Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
Open Access
- 12 December 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 10 (1) , 53-61
Abstract
We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness‐associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ERpos/HER2neg), 1953 ERneg/HER2amp, and 641 triple‐negative breast cancer (TNBC). CGP was performed using the FoundationOne® or FoundationOne®CDx NGS assay. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined in a subset of cases. PD‐L1 expression in immunocytes in a subset of cases was determined by immunohistochemistry using the companion diagnostic VENTANA PD‐L1 SP142 Assay. The median age of the cohort was 54 years (range 20–89). Genomic alterations (GAs)/tumor were similar (range: 5.9–7.3). Markers of potential immune checkpoint inhibitor (ICPI) benefit included: CD274 (PD‐L1) amplification (1%–3%), BRAF GA (1%–4%), TMB of ≥10 mutations/Mb (8%–12%), MSI‐high (0.1%–0.4%), PBRM1 GA (1%), and positive PD‐L1 staining of immunocytes ranging from 13% in ERpos/HER2neg and 33% in ERneg/HER2amp to 47% in the TNBC group. Potential markers of ICPI resistance included inactivating STK11 GA (1%–2%) and MDM2 amplification (3%–6%). MTOR pathway targets were common with lowest frequency in TNBC. ERBB2 short variant mutations were most frequent ERpos/HER2neg and absent in TNBC. BRCA1/2 GA were least frequent in ERneg/HER2amp. The demonstrations of clinical benefit of immunotherapy in MBC support the need for development and utilization of biomarkers to guide the use of ICPIs for these patients. In addition to guiding therapy selection, CGP shows potential to identify GA linked to response and resistance to ICPI in MBC.Keywords
This publication has 46 references indexed in Scilit:
- Loss of PTEN Promotes Resistance to T Cell–Mediated ImmunotherapyCancer Discovery, 2016
- Partial PTEN deletion is linked to poor prognosis in breast cancerBMC Cancer, 2015
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasClinical Cancer Research, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Environmental exposures and mutational patterns of cancer genomesGenome Medicine, 2010
- The cancer genomeNature, 2009
- Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2Clinical Cancer Research, 2004